drugset / Trial / NCT05035576

A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19

NCT05035576 ↗

Phase 1 Terminated 8 enrolled Optinose US Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine both the magnitude and duration of viral load (copies/mL) reduction after a single dose of OPN-019. The variability associated with viral counts will be utilized to inform the study design of future studies.

Timeline

Start
2021-09-01
Primary completion
2021-11-30
Completion
2021-11-30

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

EvaluationDrugModalityDoseRoute
Comparator OPN-019 Unknown 400 mg Intranasal

Indications